Chung Jacob H, Van Stavern Gregory P, Frohman Larry P, Turbin Roger E
Institute of Ophthalmology and Visual Science, UMDNJ-New Jersey Medical School, P.O. Box 1709, Newark, NJ 07101-1709, USA.
J Neurol Sci. 2006 May 15;244(1-2):133-6. doi: 10.1016/j.jns.2006.01.012. Epub 2006 Mar 9.
We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-alpha) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.
据我们所知,我们首次报道了与阿达木单抗相关的视神经炎病例,阿达木单抗是一种抗肿瘤坏死因子-α(TNF-α)拮抗剂类药物。近年来,阿达木单抗(修美乐,雅培实验室;伊利诺伊州雅培公园)已获美国食品药品监督管理局批准,它是一种重组单克隆抗体,可靶向并阻断TNF的生理作用。其他TNF拮抗剂也曾与视神经炎和脱髓鞘事件有关联。